Meeting
2023 ASCO Annual Meeting
Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers.
Authors
Egle Ramelyte
Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland
Egle Ramelyte , Laura Pawlik , Patrick Turko , Federica Sella , Natalia Maria Roshardt Prieto , Ramon Stäger , Julia-Tatjana Maul , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03458117
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9581)
DOI
10.1200/JCO.2023.41.16_suppl.9581
Abstract #
9581
Poster Bd #
344
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
First Author: Christian Grommes
Poster
2024 ASCO Annual Meeting
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
First Author: Haiyang Chen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.
First Author: Mikako Tamba
Poster
2023 ASCO Annual Meeting
Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.
First Author: Chaosu Hu